Authors Posts by Head Editor

Head Editor

5296 POSTS 18 COMMENTS

0 682

New Colombia Resources Inc. Reports Sannabis has Successfully Treated Another Prostate Cancer Patient with their Pure Cannabis Extracts

During 2004, he went through 10 sessions of radiation therapy with a PSA of 3.6; he began quarterly injections of Zoladex (Goserelin) hormone therapy. Bone scan showed no metastasis. From 2005-2013 he continued hormone therapy with yearly bone scans without metastasis with an average PSA of 9.90. In September 2013, with a PSA of 11.90, he began using Bicalutamide. In November of 2014 his bone scan was good and PSA was 12.53. In September 2015, his bone scan was good and his PSA level was 12.79.

In February 2016, his PSA jumped to 14.31 and a bone scan showed a compromising metastasis in his right femur. His PSA levels last year were: May-9.87, August-19.06, September-14.71, November-18.77, and December-18.63.

In January 2017, a CT scan revealed lumps on his lungs; he then started a treatment of Sannabis’ Pure Cannabis Indica Extract applied rectally. His PSA in January 2017 was 3.83, in February his PSA dropped to .87 and a CT scan showed the lumps had disappeared. In March, his level declined even further to .07, and last week it dropped to 0. The patient also experienced relief from a long-term case of hemorrhoids.

For the official Sannabis report on the patient visit, https://drive.google.com/open?id=0BxSKP5j2FlseU1BIU1FmSHB3eG8

These results are very encouraging to New Colombia Resources as they prepare to open treatment spas for patients from abroad that want access to quality cannabis extracts made from medicinal strains only found in Colombia, while experiencing all the natural beauty Colombia has to offer.

New Colombia Resources President John Campo is in Washington D.C. this week attending the Marijuana Business Conference and Expo held at the Gaylord National Harbor Hotel. Colombia’s year-round growing season, natural sunlight, and ideal soil continue to be of much interest and separates them from U.S. growers. Mr. Campo also met with U.S. politcians and officials at the Colombian Embassy to help promote both their coal and medical marijuana businesses. New Colombia Resources has several proposals to encourage more trade between the U.S. and Colombia in both sectors. More specific updates will be given detailing these meetings and subsequent agreements.

Sannabis and the town of Corinto-CAUCA, have organized Colombia’s first medical, therapuetic, and industrial cannabis EXPO on May 25-27. Visitors and exhibiotors are expected from around the world. For more info visit, http://corinto-cauca.gov.co/index.shtml – 2

For the Sannabis catalog visit, http://www.sannabis.co/ver-catalogo.

To view a nationally televised documentary about medical marijuana in Colombia featuring Sannabis growers, patients, and management visit the first video on http://www.sannabis.co/video. This documentary interviewed Sannabis patients and their loved ones around the country using Sannabis products.

Follow Sannabis on Facebook for photos and testimonials at https://www.facebook.com/sannabis.cannamedicinal

New Colombia Resources, Inc.

New Colombia Resources, Inc. owns vast reserves of premium metallurgical coal mining titles and a medical marijuana joint venture in the Republic of Colombia. They are setting up a rock mining operation to supply the major road and infrastructure projects within miles of their properties. They own 100% of La Tabaquera metallurgical coal mine in Colombia with an estimated 15- 17 million tonnes of reserves. They have an additional 1196 ha. metallurgical coal mining title that they are negotiating to develop with a foreign entity to build a coal fired power plant. New Colombia Resources holds a significant position in Sannabis SAS which legally produces medical marijuana products in the Republic of Colombia, visit www.sannabis.co. For more information on the Company visit www.newcolombiaresources.com

0 596

Democratic state legislators in the state of Connecticut presented a budget proposition this past Tuesday that involves regulating and taxing the use of marijuana for adults 21 and older. In the first year under the proposed system, those who are 21 and over would be able to buy controlled quantities of marijuana from existing medical marijuana dispensaries, and sales would be subject to a 25% tax in addition to the standard 6.35% state sales tax.

Once the state has licensed adult-use businesses, marijuana would be subject to an excise tax of $50 per ounce in addition to the standard 6.35% state sales tax on retail sales. Oregon and Nevada have adopted similar approaches, allowing early adult sales in medical marijuana businesses. An analysis of the plan believes it would generate roughly $60 million in marijuana tax revenue in the first full year and $180 million in the second year.

“The Democrats’ proposal to regulate marijuana for adults would generate significant new tax revenue in addition to creating jobs for residents and business opportunities for other local industries,” stated Sam Tracy, director of the Connecticut Coalition to Regulate Marijuana.

“Hundreds of millions of dollars in annual marijuana sales have been taking place in Connecticut each year, and the state has not received a dime in tax revenue. If the Legislature moves forward with this plan, the state could be bringing in hundreds of millions of dollars in new revenue within just the next two years. This is not the only reason or the best reason to regulate marijuana for adult use, but it is one of several good reasons,” says Tracy.

“Regulating marijuana would come with several public health and public safety benefits in addition to the economic benefits. It would take marijuana out of the criminal market and ensure it is tested, labeled, and sold only to adults who show proof of age. It would also allow law enforcement officials to spend more time addressing serious crimes instead of enforcing failed prohibition laws. Most Americans recognize that marijuana is safer than alcohol, and they want to see it treated that way. Kudos to the Democrats for proposing a plan that would do just that and bring a variety of benefits to the people of Connecticut,” Tracy added.

0 827

$VBIO Advisor to Present at 11th National Clinical Conference on Cannabis

Vitality Biopharma, Inc. ( OTCQB : VBIO ) (“Vitality Biopharma,” “Vitality”, or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, is pleased to announce the appointment of Dr. Caroline MacCallum MD, FRPC (Internal Medicine), BSc Pharm to its clinical advisory board.


Click Here Now To Read Full Release on (VBIO)


$RMHB Appoints Original “Shark,” Kevin Harrington to BOD

DALLAS, May 16, 2017 (GLOBE NEWSWIRE) — Rocky Mountain High Brands, Inc. (RMHB), a fully reporting consumer goods company specializing in hemp-infused food and beverage products and a naturally high alkaline water, announced today that the Company has appointed Kevin Harrington, an American entrepreneur, business executive and TV celebrity to its Board of Directors and as a marketing and communications consultant to the Company.


Click Here Now To Read Full Release on (RMHB)


$VPRB HONEY STICK brand is sponsoring the Marijuana Business Conference

VPR Brands, LP ( OTC PINK : VPRB ) will be sponsoring the Marijuana Business Conference and Expo “MJBizCon.” The Company is a named sponsor for the official Show Party of MJBizCon’s industry mixer and will have a table at the social event. This industry mixer will be today May 17 from 5-7pm, and VPR Brands, LP COO Daniel Hoff will be there to discuss updates within the Cannabis industry. Held by MJBizDaily, most speakers and exhibitors will be at the Mixer, as well as more than 1,000 of our industry peers. Also as part of our sponsorship package, our HONEYSTICK catalog will be included in up to 4,000 attendee gift bags that will be distributed at the show. The latest and greatest Honey Stick Products will be at the mixer event for Industry professionals to review.


Click Here Now To Read Full Release on (VPRB)


0 615

There’s one piece of legislation that seems to be getting a widespread of bipartisan support in Springfield.The Illinois Senate earlier this month collectively gave the green light to a bill that would allow farmers to cultivate and sell industrial hemp, a strain of cannabis. Yet unlike marijuana, industrial hemp contains less than one percent of THC, and its fiber can be used to manufacture a variety of products.

Peoria-based company Global Hemp is developing potential uses for hemp fiber, which can be chemically processed or “cottonized,” to produce a softer material.

“I want this to be that someone goes to Banana Republic, like this shirt I have on, and says, ‘wow, this is hemp? I would have thought this is cotton,’” Global Hemp President Eric Pollitt said, tugging at his plaid sleeve.

Global Hemp is also developing and researching hemp-based materials, like particle board and plastic alternatives, to be used for construction. Pollitt says a car company has already expressed interest in using his product for building prototypes.

“But they can’t say, ‘yeah, sure we’ll go ahead and make next year’s car model with hemp in it, and you guys go ahead and start growing it,’” Pollitt said. “The supply has to be there first. The demand is already there.”

Pollitt says he estimates Illinois stands to gain an economic industry, including processing and transportation, that could outpace the state’s pumpkin crop. The Industrial Hemp Bill now heads to the House.

The legislation would amend the Illinois Noxious Weed Law to allow farmers to grow hemp to be processed and sold for its fiber, seeds and oil. Hemp supporters point to neighboring Kentucky, where more than 135 farms and 40 processors have enrolled in the state’s pilot program that launched in 2016.

0 645
VPR Brands

VPR Brands HONEY STICK brand is sponsoring the Marijuana Business Conference and Expo

“MJBizDaily’s MJBizCon is the oldest and largest industry trade show event and we are proud to be a sponsor. We felt the best way to gain brand exposure and recognition was to sponsor the event and be in a select group of about five rather than an exhibit at the event and get lost in the large group of exhibitor’s. We couldn’t do better than to have our HONEYSTICK catalog included in the show gift bag and distributed to each and every attendee when they enter,” says Kevin Frija, CEO of VPR Brands, LP.

“One of my most anticipated trade conferences is always MJBizCon; it is one of the largest organized gatherings of cannabis industry professionals. With a diverse exposition and impressive speaker line-up, most industry players will be attending or exhibiting at the show. MJBizCon atmosphere is very interactive which maximizes professional networking. I look forward to a mixer and look forward to seeing everyone,” says Dan Hoff, COO VPR Brands, LP

About MJBizCon:

In 2012, we made history by launching MJBizCon, the industry’s very first national trade show. It’s by far the world’s largest gathering of executives and exhibitors each and every season. Shows in 2013, 2014, 2015 and 2016 completely SOLD OUT. The show continues to be curated by the editors of MJBizDaily, the industry’s most trusted professional news service. That may be why MJBizCon’s content is unusually strong and our attendance numbers continue to break records year after year. In May 2017, we’re anticipating 3,500-4,000 attendees from all 50 states and more than a dozen nations (including a large Canadian contingent). Attendees will include: Mid-large wholesale growers, Dispensaries and recreational retailers, Infused product makers, Ancillary companies ranging from growing technology to legal services, Angels and VCs investing in privately-held firms.

About Honey Stick:

Honey Stick is a lifestyle brand that combines the features of high tech, high performance, dependability, and affordability when it comes to upper tier vaporizers. From being the first to market in creating a Sub Ohm Vaporizer to the latest Rippo, the honey stick teams works with a vast network of growers, extractors, and industry figures to bring the needs of patients and recreational users to life. Honey Stick sells online and through a diverse network of distributors, e-tailers, dispensaries and smoke shops. For more information about VPR Brands, please visit the company on the web at http://www.vapehoneystick.com

About VPR Brands, LP:

VPR Brands is a technology company, whose assets include issued U.S. and Chinese patents for atomization related products including technology for medical marijuana vaporizers and electronic cigarette products and components. The company is also engaged in product development for the vapor or vaping market, including e-liquids. Vaporizers and electronic cigarettes (also known as e-cigarettes) are devices which deliver nicotine and or cannabis through atomization or vaping, and without smoke and other chemical constituents typically found in traditional products. For more information about VPR Brands, please visit the company on the web at www.vprbrands.com

Forward-looking statements:

This news release contains statements that involve expectations, plans or intentions and other factors discussed from time to time in the company’s Securities and Exchange Commission filings. These statements are forward-looking and are subject to risks and uncertainties, so actual results may vary materially. The company cautions readers not to place undue reliance on any forward-looking statements, which speak only as of the date made. The company disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

0 611
Florida Marijuana

The Florida Health Department made an order to stop selling a “whole flower” marijuana product that can be smoked in vaporizers, stating that it is illegal. Quincy-based Trulieve started selling “Entourage,” a whole flower product meant to be used in the Volcano vaporizer, last week.

The Health Department sent a letter to Trulieve after the News Service of Florida reported that the flower of the marijuana plant can be easily smoked in pipes, bongs, or joints, which are violations of the current medical marijuana laws.

“Licensed dispensing organizations have a responsibility to ensure their product is not one that can easily be transitioned into a smokable form. Therefore, whole flower products are not permitted,” says Christian Bax, the director of state Office of Compassionate Use.

Florida law does not permit medical marijuana smoking except using vaporizers. Trulieve’s products are in “small, wire mesh bags” in vaporizer cups. The caps can be easily removed.

The company was “surprised by the letter” but is “ immediately and completely complying with the department’s wishes while evaluating our options.” They believed that the product was legal and they had been selling the product for almost a year.

“We feel very strongly that having products available that allow patients to have a choice and to benefit from the entourage effect, also available to physicians to make recommendations to patients, is critical. So if that means we’re pushing the envelope, we’ve had a form of whole-flower vaporizer available from the day we’ve opened. This has always been part of our product line and will continue to be in the future,” says Kim Rivers, the company’s CEO.

Law makers were not able to reach an agreement on a constitutional amendment for medical marijuana regarding patients with debilitating diseases., but they all agreed on one thing: Smokable products should not be permitted.

The sale of smokable marijuana surprised the key legislators in Florida. Orlando trial lawyer John Morgan pledged to sue the state on the smoking marijuana issue, which was approved by over 71 percent of voters in November.

Advocates and patients say that the whole flower is stronger than processed products like oils or vape.

However, the state Department of Health disagrees. “The state’s marijuana operators are allowed to seek permission to sell ‘ground cannabis plant material’ meant to be vaped,” said Bad last Monday, “however, as conveyed to Trulieve in a June 28, 2016 meeting on this matter, dispensing organizations may not dispense easily breached products containing whole flower.”

He also criticized Trulieve for promoting the vaporizer but not selling it. Although it is available, the purchase of delivery products not from a dispensing organization is illegal.

“The department reminds Trulieve that all sales, possession, and use of cannabis outside of the provision” of Florida laws “are a potential criminal act,” says Bax.

0 478

Future Farm to Film Cannabis Oil Extraction Facility and LED Light Cultivation

CFN Media Group (“CFN Media”, “CannabisFN”), the leading agency and digital media network dedicated to the North American cannabis industry, today announced it will be filming Future Farm’s cannabis extraction and state-of-the-art LED grow facilities in greater Los Angeles, California over the next two weeks. The film production will explore the Company’s equipment and operational expertise in growing cannabis and extracting to produce oils and edibles. Once edited the video will be uploaded onto the Company’s website and widely distributed online.

“We are excited to be working with Future Farm Technologies on this real-time film project,” said Frank Lane, President of CFN Media. “Investors will see first-hand the depth of impact Future Farm Technologies is making on cannabis cultivation, production and consumables.”

“As we are rapidly moving into production we thought it important to share this milestone with our loyal and valued investor base,” comments Bill Gildea, CEO of Future Farm Technologies. “As we continue moving further along into production, we are now having discussions with dispensaries and distributors to purchase our oils and flower.”

For further information, contact William Gildea, Director, at 617.834.9467.

On behalf of the Board,
Future Farm Technologies Inc.
William Gildea, CEO & Chairman

About Future Farm
The Company’s business model includes developing and acquiring technologies that will position it as a leader in the evolution of Controlled Environment Agriculture (CEA) for the global production of various types of plants. Future Farm provides scalable, indoor CEA systems that utilize minimal land, water and energy regardless of climate, location or time of year and are customized to grow an abundance of crops close to consumers, therefore minimizing food miles and its impact to the environment. The Company holds an exclusive, worldwide license to use a patented vertical farming technology that, when compared to traditional plant production methods, generate yields up to 10 times greater per square foot of land. The contained system provides many other benefits including seed to sale security, scalability, consistency due to year-round production, cost control, product safety and purity by eliminating environmental variability.

The Company is also in the business of designing and distributing LED lighting solutions utilizing the COB and MCOB technology. The Company is focused on delivering cost efficient lighting to North America via advanced e-commerce sites the Company owns and operates. LEDCanada.com which caters to B2B customers is a supplier of the newest and highest demand LED solutions. The Company also owns and operates COBGrowlights.com which caters to both large and small agriculture green houses and controlled cultivation centers.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. The Canadian Securities Exchange has not in any way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.

This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.

0 370

Cara Therapeutics to Present at the 17th Annual Conference on Pain Therapeutics

  • Dr. Joseph Stauffer to deliver opening remarks and discuss kappa opioid receptor agonists as a novel approach to acute and chronic pain management

  • Dr. Stauffer serves as co-chair and on the event’s Scientific Advisory Board

Cara Therapeutics, Inc. (CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that Dr. Joseph Stauffer, Cara’s Chief Medical Officer, has been selected to speak at the 17th Annual Conference on Pain Therapeutics to be held May 22-23, 2017 in London. Dr. Stauffer also serves as an event co-chair and on the conference’s Scientific Advisory Board.

On Tuesday, May 23, Dr. Stauffer will deliver opening remarks and the opening address, during which he will discuss kappa opioid receptor agonism as a new approach to managing acute and chronic pain. This discussion will highlight positive clinical trial results and human abuse liability data for CR845, the Company’s first-in-class peripherally selective kappa opioid agonist. To date, results support the view that CR845 is unlikely to be recreationally abused or lead to physical dependence.

For more information on the 17th Annual Conference on Pain Therapeutics, visit https://www.smi-online.co.uk/pharmaceuticals/uk/pain-therapeutics.

About CR845

CR845 is a peripherally acting kappa opioid receptor agonist currently in development for the treatment of acute and chronic pain and pruritus. In multiple randomized, double-blind, placebo-controlled Phase 2 trials in patients undergoing laparoscopic hysterectomy or bunionectomy procedures, I.V. CR845 treatment resulted in statistically significant reductions in pain intensity and opioid-related side effects. In more than 1200 subjects dosed to date, CR845 was observed to be well-tolerated, without incurring the dysphoric and psychotomimetic side effects that have been reported with centrally acting (CNS-active) kappa opioid receptor agonists, and lacking the respiratory depression and abuse liability of mu opioid receptor agonists. Top-line data from a Phase 2b trial of Oral CR845 in chronic pain associated with osteoarthritis are expected in the second quarter of 2017.

About Cara Therapeutics

Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates, led by CR845, that target the body’s peripheral nervous system and have demonstrated, in Phase 2 trials, preliminary efficacy in patients with moderate-to-severe pain and pruritus without inducing many of the undesirable side effects typically associated with currently available pain therapeutics.

0 942

Vitality Biopharma Advisor to Present at 11th National Clinical Conference on Cannabis Therapeutics

Dr. MacCallum is a member of the faculty of the 11th National Clinical Conference on Cannabis Therapeutics being held in Berkeley, California May 17-20, and is presenting a talk on “Cannabis for Central Sensitivity Syndrome.” The event is sponsored by Patients out of Time a 501(c)(3) non-profit educational charity dedicated to educating healthcare professionals, organizations, and the general public about the therapeutic use of cannabis and the endocannabinoid system.

Currently, she is a clinical instructor in the Department of Medicine at the University of British Columbia (UBC) where she provides inpatient care on the Internal Medicine Ward at the UBC Hospital and Bone Marrow Transplant Ward. She is also a guest lecturer and preceptor for UBC Faculty of Pharmaceutical Sciences Pharm D Program, and the Medical director at Greenleaf Medical Clinic, a cannabis clinic in Langley, British Columbia that assesses patients’ suitability for therapy with legal, Health Canada approved medical cannabis. Dr. MacCallum’s research interests include the multimodal effects of cannabis on symptom clusters and central sensitivity syndrome, and use of cannabis for reducing polypharmacy and opioid use.

Robert Brooke, CEO of Vitality Biopharma states, “Dr. MacCallum brings a wealth of insight from her clinical experience that can guide our development of cannabinoid therapeutics. We are excited to work with her to advance our shared research interests, especially in demonstrating the ability of cannabinoids to be used as an alternative to opioid pain medications.”

About Vitality Biopharma ( OTCQB : VBIO )
Vitality Biopharma is dedicated to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders. For more information, visit: www.vitality.bio. Follow us on Facebook, Twitter and LinkedIn.

Notice Regarding Forward-Looking Statements
This news release contains “forward-looking statements” as that term is defined in Section 27(a) of the United States Securities Act of 1933, as amended and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

0 1255

Tetra Bio-Pharma Files Patent for the Treatment of Cancer and Ocular Disease

The global market for cancer drugs has hit US$100 billion in annual sales, and could reach US$147 billion by 2018, according to a new report by the IMS Institute for Healthcare Informatics. According to Transparency Market Research, the global ophthalmic drug market is expected to reach US$21.6 billion by 2018 due to high incidence of eye-related disorders amongst geriatrics. The provisional patent aims to protect new pharmaceutical combinations of cannabinoids and terpenoids to inhibit a specific signaling pathway, known as Hedgehog (Hh), and their use to combat human diseases.

“Filing of this provisional patent marks the launch of an innovative and exciting project that could not only impact patients suffering from a variety of human diseases, but also further Tetra’s interests in developing and commercializing novel cannabinoid-based pharmaceutical drugs,” said Dr. Guy Chamberland, Chief Scientific Officer of Tetra. “The rationale forming the basis for this project is well founded and our research team has extensive scientific experience in the Hh field. We look forward to quickly advancing the project through key academic collaborations, with the ultimate goal of developing multiple pharmaceutical treatments.”

Background Information:

Hh signaling is a critical developmental molecular signaling pathway and inappropriate over activation of Hh is causal in several types of human tumors, including medulloblastoma, basal cell carcinoma, rhabdomyosarcoma, and multiple forms of leukemia, as well as liver, stomach, small cell lung, prostate, and breast cancers. Hh signaling also regulates the formation and remodeling of blood vessels, and aberrant blood vessel growth is implicated in several human diseases. The eye is particularly vulnerable to dysfunctional angiogenesis and neovascularization, such as in the case of diabetic retinopathy, age-related macular degeneration, neovascular glaucoma, retinal vein occlusion and retinopathy of prematurity, where inappropriate ocular blood vessel growth often leads to irreversible blindness if left untreated.

Currently, there are few clinically approved treatments for Hh-pathway-dependent cancers and drug resistance remains a major hurdle. As well, current treatment approaches to neovascular and angiogenic ocular disease are insufficiently effective and have significant adverse effects. Thus, there is a large need to develop novel therapies to treat human cancers and ocular disease related to blood vessel growth. Recently, cannabinoids have emerged as novel and potent inhibitors of the Hh signaling pathway and terpenoids have been shown to modulate the effects of cannabinoids through an undefined mechanism. Tetra looks to capitalize on these recent findings by filing a provisional patent for the use of cannabinoids in combination with terpenoids to treat Hh related cancer growth and aberrant blood vessel growth in the eye. Securing a provisional patent and achieving the freedom to operate is an important first step in the realization of this project.

About Tetra-Bio Pharma:

Tetra Bio-Pharma is a multi subsidiary publicly traded company (CSE:TBP)(GRPOF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.

Tetra Bio-Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.tetrabiopharma.com.

The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Marijuana Stocks, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact privacy@marijuanastocks.com
Ad Placements